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Abstract
Despite their potential, conventional whole-cell cancer vaccines prepared by freeze-thawing or 
irradiation have shown limited therapeutic efficacy in clinical trials. Recent studies have indicated 
that cancer cells treated with certain chemotherapeutics, such as mitoxantrone, can undergo 
immunogenic cell death (ICD) and initiate antitumor immune responses. However, it remains 
unclear how to exploit ICD for cancer immunotherapy. Here, we present a new material-based 
strategy for converting immunogenically dying tumor cells into a powerful platform for cancer 
vaccination and demonstrate their therapeutic potential in murine models of melanoma and colon 
carcinoma. We have generated immunogenically dying tumor cells surface-modified with 
adjuvant-loaded nanoparticles. Dying tumor cells laden with adjuvant nanodepots efficiently 
promote activation and antigen cross-presentation by dendritic cells in vitro and elicit robust 
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antigen-specific CD8α+ T-cells in vivo. Furthermore, whole tumor-cell vaccination combined with 
immune checkpoint blockade leads to complete tumor regression in ~78% of CT26 tumor-bearing 
mice and establishes long-term immunity against tumor recurrence. Our strategy presented here 
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While various technologies, including micelles, lipid vesicles, polymers, and inorganic 
nanomaterials, have been developed as the delivery platforms for cancer vaccination,1–8 it 
remains challenging to achieve robust antitumor efficacy with therapeutic potential against 
established tumors. Cancer vaccines employing defined tumor antigens require extensive 
antigen discovery and optimization processes, but tumor cells can escape the immune 
pressure by antigen down-regulation and immunosuppression.9 Notably, recent reports 
suggest that cancer cells treated with certain anthracyclines undergo immunogenic cell death 
(ICD),10,11 during which dying tumor cells release immunostimulatory “danger” signals 
(e.g., high mobility group box 1 (HMGB1),12 calreticulin,13 and ATP14) to break immune 
tolerance and initiate antitumor immune responses.11,15 While this discovery suggests an 
entirely new therapeutic approach, it remains unclear how to exploit ICD as a new basis for 
cancer vaccination. This unmet need is underscored by the limited patient response rates to 
immune checkpoint blockers (ICBs) that remove immunosuppressive “brakes” on T-cells.
16,17
 If we can harness the potency of ICD to initiate antitumor immunity against a wide 
repertoire of antigens released from patients’ dying tumor cells and “liberate” antitumor T-
cells with ICBs, this could lead to a powerful and generalizable strategy for “personalized” 
cancer immunotherapy.
Here, we present a novel synthetic approach for converting immunogenically dying tumor 
cells into a versatile platform for cancer vaccination and demonstrate their therapeutic 
potential in multiple murine tumor models. Specifically, we have utilized immunogenically 
dying tumor cells as the source of both tumor antigens and “danger” signals and amplified 
their potency by surface-modification of dying tumor cells with adjuvant-loaded nanodepots 
(Figure 1A). We demonstrate that our whole tumor-cell vaccine approach efficiently 
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promotes activation and antigen presentation by antigen-presenting cells (APCs) and elicits 
strong antitumor immune responses in murine models of melanoma and colon carcinoma. 
Importantly, dying tumor cells laden with adjuvants in combination with ICBs exhibited 
remarkable therapeutic potential, leading to complete tumor regression and long-term 
protection against tumor recurrence in ~78% of tumor-bearing animals.
First, we designed a new nanodepot platform (NP) for colocalized delivery of 
immunostimulatory ligands from immunogenically dying tumor cells. We chose to work 
with CpG oligonucleotide, a potent Toll-like receptor-9 (TLR9) agonist known to promote 
antigen cross-presentation and cross-priming of CD8+ T-cell responses.18 We constructed 
cross-linked lipid-polymer nanodepots by utilizing the charge-mediated complexation 
between cationic lipid vesicles containing a maleimide-modified lipid and a thiolated 
anionic biopolymer, hyaluronic acid (HA-SH).19 Subsequent chemical cross-linking led to 
the formation of multilamellar lipid-polymer hybrid nanodepots (Figure 1B). Briefly, we 
first synthesized the functional lipid DOBAQ-MAL using the EDC/NHS chemistry (Figure 
S1A). DOBAQ was successfully modified with a maleimide group, as shown by the results 
of thin layer chromatography (Figure S1B) and 1H NMR (Figure S2) with the reaction rate 
of 95% as determined by high-performance liquid chromatography (Figure S1C). Next, we 
prepared unilamellar liposomes (composed of DOBAQ-MAL, DOTAP, and DOPC) and 
incubated them with HA-SH and CpG, resulting in stable NPs. Maleimide-sulfhydryl-
mediated cross-linking was crucial for the formation of homogeneous NPs, as aggregates 
were formed when we replaced DOBAQ-MAL (+1 charge) with DOTAP (+1 charge), or 
when we replaced HASH with HA-bearing the same amount of negative charges (data not 
shown).
We also optimized nanodepots by varying the amounts of HA-SH. Homogenous NPs with a 
diameter <300 nm were formed when the charge ratio of cations to anions (from cationic 
lipids and HA subunits, respectively) was set at =2 (Figure 1C,D). Therefore, we performed 
the subsequent studies using NPs formulated with 0.63 μmol of total lipids (DOBAQ-MAL/
DOTAP/DOPC = 25:50:25, m/m/m) and 100 μg of HA-SH (~0.25 μmol of subunits) with 
the cation to anion ratio of 1.89. Compared with unilamellar liposomes, these lipid-polymer 
hybrid NPs exhibited a slightly increased particle size of 250 ± 13 nm with their surface 
charge converted to −16 ± 0.4 mV (Table S1). The resulting NPs had an average of ~2300 
reactive maleimide molecules displayed on each particle, with 28% of lipids exposed on the 
external surfaces of NPs (as opposed to 45% for unilamellar liposomes) with 81 ± 2% of 
CpG loading efficiency (Table S1 and S2). These results indicate the successful synthesis of 
maleimide-displaying, multilamellar NPs loaded with CpG (CpG-NPs).
We then tethered CpG-NPs on the surfaces of dying tumor cells. We first characterized 
tumor cells undergoing ICD after treatment with mitoxantrone (Mit), a potent ICD-inducing 
anthracenedione agent.13 B16F10OVA melanoma cells expressing an exogenous antigen, 
ovalbumin (OVA), were exposed to 10 μM Mit for 12 h and washed. After 2 days of culture, 
the majority of tumor cells exhibited signs of apoptosis, as indicated by ~80% of the 
Annexin V+ cell population (Figure 2A) and released HMGB1 (Figure 2B), a marker of 
ICD.12 Live as well as immunogenically dying tumor cells have free sulfhydryls on 
endogenous cell-membrane proteins (as shown by cells stained with Oregon Green-
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Maleimide, Figure 2C). Thus, we have sought to utilize free sulfhydryls on the surfaces of 
immunogenically dying tumor cells to attach maleimide-displaying CpG-NPs. A brief 
treatment of dying tumor cells with 1 mM TCEP, a reducing agent, increased free 
sulfhydryls on the cell membrane by a 2.5-fold, compared with dying tumor cells without 
the TCEP treatment (Figure 2C). Preblocking Oregon Green-Maleimide with 100 molar 
excess of L-cysteine led to ~27-fold reduction in the mean fluorescence intensity (MFI) of 
cells, showing its specificity toward free thiols on the cells (Figure 2C). Overnight 
incubation of Mit- and TCEP-treated cells with NPs at 4 °C led to the successful surface-
conjugation of NPs in a dose-dependent manner (Figure 2D,E, and Movie S1). When cell-
NP conjugates were treated with trypan blue, a cell membrane-impermeable fluorescence-
quencher,20,21 ~96% of cell-associated fluorescence signal was quenched (Figure 2F), 
indicating cell-surface conjugation, rather than internalization, of NPs. In contrast, elevating 
the incubation temperature from 4 to 37 °C resulted in ~50% of the NPs internalized by 
tumor cells within 1 h (Figure S3). Mit-treated B16F10OVA cells decorated with NPs 
displayed the prototypical markers of ICD (Figure S4).
We next asked whether dying tumor cells modified with CpG-NPs can recruit and activate 
dendritic cells (DCs). In particular, successful cross-priming of CD8α+ T-cells by DCs 
requires three signals: (1) antigen processing and presentation in the context of major 
histocompatibility complex (MHC) class I molecule; (2) up-regulation of costimulatory 
markers, such as CD40, CD80, and CD86; and (3) secretion of TNF-α and IFN-β that 
mediate inflammatory and innate immune responses,22,23 as well as Th1 cytokines, such as 
IL-12.24,25 Indeed, we observed that Mit-treated tumor cells significantly increased DC 
recruitment (a 2.4-fold increase than live tumor cells, P < 0.001, Figure 3A). DCs engulfed 
Mit-treated tumor cells 4.2-fold more efficiently than live tumor cells (P < 0.001, Figure 
3B). We next examined cross-presentation of tumor antigens engulfed by DCs. As shown by 
staining with a 25-D1.16 monoclonal antibody directed against SIINFEKL-H-2Kb 
complexes,7 cross-presentation of OVA protein from B16F10OVA cells was significantly 
enhanced when DCs were cocultured with dying tumor cell-CpG-NP conjugates, compared 
with tumor cells admixed with the equivalent dose of free CpG or CpG-NPs (P < 0.001, 
Figure 3C). Moreover, surface-decoration of dying tumor cells with CpG-NPs was important 
for maturation and up-regulation of CD40 and CD86 on DCs (P < 0.001, Figure 3D,E, 
Figure S5). Similarly, dying tumor cell-CpG-NP conjugates promoted robust secretion of 
inflammatory cytokines from DCs, including IL-12p70 (only detected for dying tumor cell-
CpG-NP conjugates, Figure 3F), TNF-α, and IFN-β (P < 0.001, Figure 3G,H). Overall, 
surface-conjugation of CpG-NPs on dying tumor cells, rather than their physical mixture, 
was crucial for strong DC maturation, antigen cross-presentation, and cytokine secretion.
Having shown DC activation in vitro, we examined whether the whole tumor-cell vaccine 
can elicit antitumor CD8α+ T-cell responses in vivo. We immunized naive C57BL/6 mice 
subcutaneously (s.c.) at tail base with a single dose of vaccine (4 × 106 Mit-treated 
B16F10OVA cells with 380 ng CpG per dose). On day 7, the frequency of CD8α+ T-cells 
against the immunodominant epitope of OVA, SIINFEKL, was measured by the tetramer 
staining assay on the peripheral blood mononuclear cells (PBMCs) (Figure 4A).26,27 
Whereas vaccination with dying tumor cells alone resulted in minimal induction of 
SIINFEKL-specific CD8α+ T-cells, dying tumor cell-CpG-NP conjugates generated strong 
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antigen-specific CD8α+ T-cell responses (3.2-fold greater than PBS, P < 0.01; and 2.4-fold 
greater than dying tumor cells, P < 0.05, Figure 4B). Similar results were also found among 
splenocytes (Figure S6). We also restimulated splenocytes from immunized mice with whole 
B16F10OVA cells and found that dying tumor cell-CpG-NP conjugates elicited significantly 
higher levels of IFN-γ+ CD8α+ and CD4 T-cells, compared with dying tumor cells without 
CpG (P < 0.05, Figure 4C,D). To assess the functionality of these CD8α+ T-cells, we 
inoculated the animals with 105 B16F10OVA tumor cells s.c. on day 8. A single 
immunization with dying tumor cell-CpG-NP conjugates protected all animals against tumor 
initiation (Figure 4E,F). In contrast, vaccination with dying tumor cells alone failed to stop 
B16F10OVA tumor growth (P < 0.01, Figure 4E) with only 20% survival rate (P < 0.05, 
Figure 4F). These results demonstrated the potency of the dying tumor cell-CpG-NP 
conjugates to generate antitumor T-cell immune responses in vivo.
Next, we evaluated our vaccination strategy in a therapeutic setting against established CT26 
colon carcinoma (without any exogenous antigen) to provide a more rigorous condition than 
the prophylactic setting shown above. We confirmed that Mit treatment induced ICD in 
CT26 cells and that CpG-NPs were successfully conjugated on CT26 cells (Figure S7). 
BALB/c mice were inoculated at s.c. flank with 2 × 105 CT26 cells, and on day 4 when 
tumors were palpable, a single dose of vaccine was administered. The dying tumor cell-
CpG-NP conjugates significantly inhibited CT26 tumor growth (P < 0.001, compared with 
PBS or dying tumor cells alone, Figure S8), whereas dying tumor cells physically admixed 
with the equivalent dose of soluble CpG or CpG-NPs failed to reduce the tumor size. Taken 
together with the data shown in Figure 3, these results show that surface-conjugation of 
CpG-NPs on dying tumor cells, rather than their physical mixture, was crucial for potent 
immune responses and antitumor efficacy.
Lastly, we sought to amplify the therapeutic potential of our whole-cell vaccine by 
combining with ICBs. This was motivated by the low patient response rates to ICBs,28,29 
highlighting the need to improve the outcomes of cancer immunotherapy. We treated CT26 
tumor-bearing mice with dying tumor cell-CpG-NP conjugates combined with anti-PD1 IgG 
therapy (Figure 5A). The combination immunotherapy exerted robust anti-tumor efficacy, 
leading to potent inhibition of average tumor growth (P < 0.001, Figure 5B) and complete 
elimination of tumors in ~78% of animals (Figure 5C). In contrast, mice that received anti-
PD1 monotherapy or dying tumor-cell vaccine alone failed to stop the average tumor growth 
in this model. Importantly, 100% of the survivors in the whole tumor-cell vaccine plus anti-
PD1 treatment group rejected engraftment of 2 × 105 CT26 tumor cells rechallenged on day 
70 (P < 0.001, Figure 5D), demonstrating long-term immunity against tumor recurrence. 
Moreover, throughout our studies we did not observe any signs of weight loss, toxicity, 
reactogenicity at the sites of vaccination, nor autoimmunity in animals treated with the 
combination immunotherapy. Collectively, these studies show that surface-modification of 
immunogenically dying tumor cells with adjuvant-carrying nanodepots rendered them into a 
potent vaccine platform with therapeutic potential.
In summary, we induced ICD of tumor cells by treating them with mitoxantrone and 
exploited immunogenically dying tumor cells as the platform for codelivery of tumor 
antigens and immunostimulatory agents. To promote immune activation, we have tethered 
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CpG-NPs onto the surfaces of dying tumor cells via sulfhydryl-maleimide chemistry, a facile 
cell-engineering approach that has been utilized on therapeutic T-cells.30,31 Notably, our 
strategy based on nanodepots achieve codelivery of adjuvants without their premodification 
with cell-anchoring structures,32,33 or prelabeling of cells with metabolic ligands or 
antibodies34,35 and could deliver a single or potentially multiple synergistic TLR agonists.36 
Here, we have demonstrated that immunogenically dying tumor cells decorated with CpG-
NPs recruited DCs (Figure 3A), promoted DC maturation (Figure 3D–H), uptake of tumor 
antigens (Figure 3B), and subsequent antigen cross-presentation (Figure 3C), thereby 
triggering robust antigen-specific T-cell responses with antitumor efficacy in vivo (Figure 4). 
Importantly, by employing a combination approach with anti-PD1 therapy, we achieved 
regression of established CT26 tumors in ~78% of mice and protected them against future 
tumor relapse (Figure 5). Furthermore, a single vaccine dose employed in this study would 
simplify the immunization scheme and increase the translational potential of our strategy. To 
the best of our knowledge, we demonstrate for the first time that immunogenically dying 
tumor cells engineered to release exogenous adjuvants can exert potent prophylactic as well 
as therapeutic antitumor efficacy in multiple murine tumor models. We are currently 
exploring ways to codeliver ICD inducers and immunostimulatory molecules to tumors in 
vivo for generating whole tumor-cell vaccines in situ without ex vivo manipulations. 
Looking forward, we provide a general framework for exploiting ICD of tumor cells for 
elicitation of immunity against a wide repertoire of antigens found in whole tumor cells 
without a priori knowledge of antigens. Our strategy may open new avenues to 
“personalized” cancer immunotherapy tailored to individual patient’s tumor cells.
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Exploiting ICD for cancer immunotherapy. (A) Immunogenically dying tumor cells surface-
decorated with TLR agonist-loaded nanoparticles release tumor antigens and damage-
associated molecular patterns, triggering activation of dendritic cells and induction of tumor-
specific CD8α+ T-cells that can kill tumor cells. Combination of the whole-cell vaccine with 
PD1 blockade further improves therapeutic efficacy. (B) The lipid-polymer hybrid 
nanoparticle (NP) encapsulating the TLR9 agonist CpG was constructed by complexation 
between cationic liposomes and thiolated HA-SH, an anionic biopolymer, followed by cross-
link-mediated stabilization. (C) NP synthesis was optimized by varying the charge ratio 
between cationic lipids and HA-SH. Particle size and zeta potential were measured by DLS. 
Results are means ± SEM, n = 3. (D) A representative CpG-loaded NP visualized by 
transmission electron microscopy with negative staining. Scale bar, 20 nm.
Fan et al. Page 9






















Surface-modification of immunogenically dying tumor cells with CpG-NPs. (A,B) 
Mitoxantrone (Mit) induced immunogenic cell death of tumor cells. B16F10OVA cells were 
treated by 10 μM mitoxantrone for 12 h, followed by media change and cell culture for 2 
days. (A) Cell death and (B) cellular release of HMGB1 were measured by Annexin V/PI 
staining and ELISA, respectively. Numbers in the representative flow cytometry plots 
indicate the percentage of live, apoptotic, and necrotic cell populations. (C) Mit-treated 
tumor cells exhibited free thiol groups on their surfaces, and treatment with 1 mM TCEP 
further increased the level of free thiols, as shown by the representative flow cytometry 
analysis from two independent experiments. MFI, geometric mean fluorescence intensity. 
Preblocking of Oregon Green-Maleimide (with 100 molar-excess L-cysteine decreased the 
MFI. (D) The number of NPs bound on dying tumor cells was quantified after incubation of 
106 Mit-treated B16F10 cells at 4 °C for 12 h with varying doses of fluorophore-labeled 
CpG-NPs. (E) The representative confocal images of a dying tumor cell (green) conjugated 
with NPs (red) and their 3D reconstruction. Scale bar, 5 μm. (F) In the presence of trypan 
blue (a membrane-impermeable quencher), fluorescence signal from cell-associated NPs 
was lost, indicating that NPs were attached externally to the cell membrane. Data in 
(A,B,D,F) show mean ± SEM (n = 3), representative from 2 to 3 independent experiments. * 
P < 0.05, *** P < 0.001, analyzed by one-way ANOVA with Bonferroni multiple 
comparison post-test.
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Immunogenically dying tumor cells conjugated with CpG-NPs activate DCs. (A) Mit-treated 
B16F10OVA tumor cells promoted recruitment of BMDCs as measured by the Transwell 
migration assay. (B,C) Mit-treated tumor cells were efficiently engulfed and cross-presented 
by BMDCs. BMDCs were cocultured with Oregon Green-labeled, Mit-treated B16F10OVA 
cells for 24 h, followed by (B) quantification of tumor antigen-positive BMDCs and (C) 
SIINFEKL display among antigen-positive BMDCs by flow cytometry. Group legends for 
panels (B–H) are shown in panel (B). (D–H) Dying tumor cells conjugated with CpG-NPs 
induced up-regulation of (D) CD40 and (E) CD86 on BMDCs and promoted BMDCs to 
secrete inflammatory cytokines, including (F) IL-12p70, (G) TNF-α, and (H) IFN-β, as 
measured by ELISA. ND, not detected. The data show mean ± SEM, from a representative 
experiment (n = 3) from 2 to 3 independent experiments. ** P < 0.01, *** P < 0.001, 
analyzed by one-way ANOVA with Bonferroni multiple comparison post-test.
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Immunogenically dying tumor cells membrane-decorated with CpG-NPs elicit antitumor T-
cell responses in vivo. (A) C57BL/6 mice were vaccinated with 4 × 106 Mit-treated 
B16F10OVA cells, followed by tetramer staining for antigen-specific CD8α+ T-cells on day 
7, and intracellular IFN-γ staining or tumor-cell challenge on day 8. (B) The frequency of 
SIINFEKL-specific CD8α+ T-cells among peripheral blood mononuclear cells (PBMCs) and 
their representative flow cytometry scatter plots are shown. (C,D) Splenocytes from 
immunized mice were restimulated with live B16F10OVA cells ex vivo, and the percentages 
of IFN-γ+ among (C) CD8α+ and (D) CD4+ splenocytes are shown. (E,F) Vaccinated mice 
were challenged with live B16F10OVA cells, and (E) average tumor volumes and (F) tumor-
free percentages are shown. The data show mean ± SEM, (n = 10 for panels (B–D); n = 4–5 
for panels (E,F)), analyzed by (B–D) one-way ANOVA, (E) two-way ANOVA with the 
Bonferroni multiple comparison post-test, or (F) the log-rank (Mantel-Cox) test. (B–D,F) * 
P < 0.05, ** P < 0.01, *** P < 0.001. (E) ** P < 0.01, *** P < 0.001 versus the PBS control; 
##
 P < 0.01 versus the Mit-B16F10OVA group.
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Immunogenically dying tumor cells conjugated with CpG-NPs exert potent antitumor 
efficacy in combination with immune checkpoint blockade. (A–D) BALB/c mice were 
inoculated with 2 × 105 CT26 cells subcutaneously on day 0, then treated with a single dose 
of the whole-cell vaccine (106 Mit-CT26-CpG-NPs) on day 4 when tumors were palpable, 
followed by anti-PD1 IgG therapy (clone: RMP1-14, 100 μg) every 3 days from day 5 to day 
26. (B) The average tumor growth volumes are shown until day 20 when mice bearing large 
or ulcerated tumors had to be euthanized. (C) Individual tumor growth curves are shown. 
CR, complete regression. (D) Tumor growth was monitored after rechallenge of mice cured 
by the combination therapy (n = 7) with 2 × 105 CT26 tumor cells on day 70. Naive mice (n 
= 5) were used as control. The data show mean ± SEM from a representative experiment 
with n = 8–9 for panel (B,C) from two independent experiments, analyzed by (B) two-way 
ANOVA with Bonferroni multiple comparison post-test, or (D) log-rank (Mantel-Cox) test. 
(B) * P < 0.05, ** P < 0.01, *** P < 0.001 versus the control group; ## P < 0.01, ### P < 
0.001 versus the anti-PD1 group.
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